Researchers have investigated the effectiveness of LY2801653, a potent inhibitor that targets both MET and RON tyrosine kinase receptors, which are known to be overexpressed in non-small cell lung cancer (NSCLC). This evidence concerns the gene MET and non-small cell lung carcinoma.